Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

Jorge Cortes, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William Wierda, Mary B. Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop Kantarjian

Research output: Contribution to journalArticle

148 Scopus citations

Abstract

Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia and organ involvement. Different treatments have been investigated in HES with modest success. It has been suggested that imatinib is active in HES. We treated 9 patients with HES with 100 mg imatinib daily. Doses for patients without response after 4 weeks were increased to 400 mg daily. Prior therapy had failed for 7 patients. Five patients responded: 4 achieved sustained complete remission lasting a median of 12+ weeks (range, 9+ to 36+ weeks), and 1 had a transient response. One patient died in complete remission. Responses occurred within 4 weeks of therapy; only 1 responder required an increase in dose to 400 mg daily. Three of 4 nonresponders failed to respond to an increase in dose. Toxicity was minimal. We conclude that imatinib therapy is effective for HES.

Original languageEnglish (US)
Pages (from-to)4714-4716
Number of pages3
JournalBlood
Volume101
Issue number12
DOIs
StatePublished - Jun 15 2003
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome'. Together they form a unique fingerprint.

  • Cite this

    Cortes, J., Ault, P., Koller, C., Thomas, D., Ferrajoli, A., Wierda, W., Rios, M. B., Letvak, L., Kaled, E. S., & Kantarjian, H. (2003). Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 101(12), 4714-4716. https://doi.org/10.1182/blood-2003-01-0081